0001181431-13-046220.txt : 20130823
0001181431-13-046220.hdr.sgml : 20130823
20130823080029
ACCESSION NUMBER: 0001181431-13-046220
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130821
FILED AS OF DATE: 20130823
DATE AS OF CHANGE: 20130823
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MAIN STREET
STREET 2: SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: 101 MAIN STREET
STREET 2: SUITE 1850
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scheer David
CENTRAL INDEX KEY: 0001378585
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 131056245
MAIL ADDRESS:
STREET 1: ACHILLION PHARMACEUTICALS
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
rrd388969.xml
FORM 4
X0306
4
2013-08-21
0
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001378585
Scheer David
C/O AEGERION PHARMACEUTICALS, INC.
101 MAIN STREET, SUITE 1850
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
10000
D
Common Stock
640154
I
See Footnote
Common Stock
2013-08-21
4
S
0
19600
84.572
D
620554
I
See Footnote
Common Stock
2013-08-21
4
S
0
400
85.068
D
620154
I
See Footnote
The Reporting Person, David Scheer, is the managing member of Scheer Investment Holdings VII LLC. Mr. Scheer disclaims beneficial ownership except to the extent of his proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.03 to $85.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Anne Marie Cook, attorney-in-fact
2013-08-23